Mitochondrial metabolism in multiple myeloma cells
Universita degli Studi di Catania
Division of Hematology, Az. Ospedaliero- Universitaria Policlinico, via Santa Sofia, 86, CAP 95123, University of Catania, Catania, Italy
Dott.ssa Cesarina Giallongo, dott. DanieleTibullo,
Dott.ssa Cesarina Giallongo, dott. DanieleTibullo,
English; Italian
4 weeks
Cities/Months Jan Feb Mar Apr May Jun Jul Augt Sep Oct Nov Dec
No No No No No No No Yes No No No No
Type of Research Project
- Clinical Project with Laboratory work
What is the background of the project?
Multiple myeloma (MM) is a haematological cell disorder characterized by the secretion of antibodies and a complex array of clinical manifestation including hypercalcemia, renal dysfunction anaemia and bone lesions. MM consist of a spectrum of clinical variants ranging from benign MGUS and smouldering/indolent MM, to more aggressive, disseminated forms of MM and plasma cell Leukaemia. Despite recent advances in proteasome inhibitor and immunomodulatory drug-based therapies, MM remains largely incurable, primarily owing to acquired resistance to anti-myeloma chemotherapeutic drugs.
What is the aim of the project?
The aims of this project are: - Investigate the inter-relationship between the altered mitochondrial metabolism in MM cells, ROS generation, their adaptation to intrinsic oxidative stress, and mitochondrial biogenesis. - Analyze the systemic impact of oxidative stress in MM patients, expecially in relation to immune deregulations. - Investigate the mitochondrial role of HO-1 in the hyperactive metabolic pathway of MM cells including its role in bortezomib resistance.
What techniques and methods are used?
The student will perform: - In the first step, cell culture techniques and analysis of transcriptome databases are used. - In the second step, flow cytometry will be used to detect and measure physical and chemical characteristics of multiple myeloma cells, even exposed to bortezomib. - In the third step, to analyze the systemic impact of oxidative stress on gene expression(especially on mitochondrial metabolism), - in the fourth step, RT-PCR (Reverse transcriptase-polymerase chain reaction) is used: In RT-PCR, the RNA template is first converted into a complementary DNA (cDNA) using a reverse transcriptase. The cDNA is then used as a template for exponential amplification using PCR for mitochondrial gene expression. - In the fifth step, the serum samples of patients with multiple myeloma are collected and analyzed even through ELISA (Enzyme-Linked Immuno Sorbent assay).
What is the role of the student?
- The student will mainly observe
- The student will observe the practical experiments but will be highly involved in the analysis of the results
- If the project includes “lab work”
- the student will take active part in the practical aspect of the project
- The tasks will be done under supervision
What are the tasks expected to be accomplished by the student?
The student is supposed to attend regularly the research internship, to be cooperative. It will be important to participate willingly to the activities, maybe giving new point of view to the tutor. Students will follow the entire process of the experiments and will be able with time to conduct experiment by him/herself. In addition students could follow the ward and outpatients activity and could be able to integrate information coming from the lab with clinical features of the patients.
Will there be any theoretical teaching provided (preliminary readings, lectures, courses, seminars etc)
What is expected from the student at the end of the research exchange? What will be the general outcome of the student?
- No specific outcome is expected
What skills are required of the student? Is there any special knowledge or a certain level of studies needed?
Are there any legal limitations in the student’s involvement
Type of students accepted
This project accepts:
- Medical students
- Graduated students (less than 6 months)
- Pre-Medical students from the American-British system
- Dasanu CA. Immune alterations in untreated and treated multiple myeloma. J Oncol Pharm Pract 2012; 18: 257-263.